Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Sarcoma 1Recurrent Malignant Solid Neoplasm 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Metastatic Castration-Resistant Prostate Cancer 1Malignant Neoplasms of Digestive Organs 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Liver Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1Advanced Solid Tumor 1

Interventions

pembrolizumab 37Gemcitabine 29Nivolumab 20Cisplatin 19atezolizumab 15avelumab 14Docetaxel 13enfortumab vedotin 10Carboplatin 10durvalumab 9Magnetic Resonance Spectroscopy 9Ipilimumab 8Paclitaxel 7Pemetrexed 6toripalimab 5cabozantinib 5Fluorodeoxyglucose F18 5sacituzumab govitecan 4cabazitaxel 4Taxes 4vinflunine 3tremelimumab 3pemigatinib 3X-Rays 3Standard of Care 3Specimen Handling 3Radiotherapy 3Mitomycin 3Immunotherapy 3Immunoglobulin G 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Transitional Cell × sapanisertib × Clear all
NCT03745911 2018-11-19

Paclitaxel and TAK-228 in Urothelial Carcinoma

Associació per a la Recerca Oncologica, Spain

Phase 2 Unknown
52 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡